BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
BioMarin announced positive results from the pivotal Phase 3 CANOPY-HCH-3 study for VOXZOGO in children with hypochondroplasia. The study met its primary endpoint, showing a statistically significant annualized growth velocity improvement of 2.33 cm/yr versus placebo (p<0.0001), along with significant gains in standing height, height Z-score, and arm span. Safety findings were consistent with the established profile in achondroplasia with no new signals.
Key figures
- Drug Name
- VOXZOGO (vosoritide)
- Phase Of Trial
- Phase 3
- Study name
- CANOPY-HCH-3
- Patient count
- 80
- Agv improvement
- 2.33 cm/yr
- P value primary
- <0.0001
- Snda submission timing
- Q3 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.